Molecular-based imaging provides new opportunities to assess vital cellular processes in vivo. The ability tomonitor the molecular processes of cancer via non-invasive imaging may provide critical informationregarding the effects of therapy. In the context of pre-clinical research, the use of in vivo imaging permits theacquisition of a complete dynamic biodistribution study in each animal, thereby reducing the number ofanimals required to reach a statistically adequate result; often the techniques used in small animal imagingare directly transferable to the clinical setting. The Small Animal Imaging Core (SAIC) is a new sharedresource dedicated to providing investigators access to the state-of-the-art in small animal imagingcapabilities for use in basic and translational research relevant to the mission of the City of Hope CancerCenter.
Specific aims of the SAIC include: (1) maintaining a thorough understanding of the currentcapabilities and limitations of small animal imaging as they pertain to cancer research; (2) implementing,developing, calibrating, maintaining, and operating relevant imaging systems within the context of a smallanimal imaging laboratory; and (3) optimizing the use of small animal imaging in research at City of Hope byconsulting with investigators. Core personnel currently include a Director, an imaging physicist, and amanager, all of whom are highly experienced in the use of imaging for research with animals. Small animalimaging systems in operation include two units for bioluminescence optical imaging (I VIS 100, XenogenCorp.); a gamma camera (Y IMAGER, Biospace, Inc.); a PET scanner (microPET R4, CTIMI, Inc.); and a CTscanner (microCAT II Hi Res, CTIMI, Inc.). The microPET and microCAT are readily used in tandem togenerate co-registered functional-anatomic PET/CT images. The Animal Resources Center has providedfour rooms within the Parvin Biomedical Research Building for use by the animal imaging program (one roomfor the microPET, microCAT, and the y-IMAGER; two rooms for the Xenogen MS machines; and one roomfor a gamma counter). A system has been developed for billing users for a portion of the costs of the imagingprocedures. During the first 12-month reporting period, the SAIC was used by 13 Cancer Center membersfrom 3 Research Programs and peer-reviewed usage represented 89% of total usage. Annual budget for thecore is $165,922 (97% institution, 3% chargebacks); 42% ($70,000) is being requested from the CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA033572-25
Application #
7714127
Study Section
Subcommittee G - Education (NCI)
Project Start
2008-09-01
Project End
2012-11-30
Budget Start
2008-09-01
Budget End
2008-11-30
Support Year
25
Fiscal Year
2008
Total Cost
$49,650
Indirect Cost
Name
City of Hope/Beckman Research Institute
Department
Type
DUNS #
027176833
City
Duarte
State
CA
Country
United States
Zip Code
91010
Gast, Charles E; Silk, Alain D; Zarour, Luai et al. (2018) Cell fusion potentiates tumor heterogeneity and reveals circulating hybrid cells that correlate with stage and survival. Sci Adv 4:eaat7828
Salgia, Ravi; Kulkarni, Prakash (2018) The Genetic/Non-genetic Duality of Drug 'Resistance' in Cancer. Trends Cancer 4:110-118
Yoon, Sorah; Wu, Xiwei; Armstrong, Brian et al. (2018) An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma. Mol Ther Nucleic Acids 14:131-141
Yim, John H; Choi, Audrey H; Li, Arthur X et al. (2018) Identification of Tissue-Specific DNA Methylation Signatures for Thyroid Nodule Diagnostics. Clin Cancer Res :
Wang, Tianyi; Fahrmann, Johannes Francois; Lee, Heehyoung et al. (2018) JAK/STAT3-Regulated Fatty Acid ?-Oxidation Is Critical for Breast Cancer Stem Cell Self-Renewal and Chemoresistance. Cell Metab 27:136-150.e5
Magilnick, Nathaniel; Boldin, Mark P (2018) Molecular Moirai: Long Noncoding RNA Mediators of HSC Fate. Curr Stem Cell Rep 4:158-165
Yun, Xinwei; Zhang, Keqiang; Wang, Jinhui et al. (2018) Targeting USP22 Suppresses Tumorigenicity and Enhances Cisplatin Sensitivity Through ALDH1A3 Downregulation in Cancer-Initiating Cells from Lung Adenocarcinoma. Mol Cancer Res 16:1161-1171
Herrera, Alex F; Rodig, Scott J; Song, Joo Y et al. (2018) Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biol Blood Marrow Transplant 24:514-520
Slavin, Thomas P; Banks, Kimberly C; Chudova, Darya et al. (2018) Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing. J Clin Oncol :JCO1800328
Shahin, Sophia A; Wang, Ruining; Simargi, Shirleen I et al. (2018) Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer. Nanomedicine 14:1381-1394

Showing the most recent 10 out of 1396 publications